Mitochondria ATP Pro-Ferroptosis by Adjusting the Conversion of PUFA to PUFA-PLs

Abstract

Ferroptosis is a form of iron-dependent regulated necrosis characterized by the abnormal accumulation of peroxidized phospholipids containing polyunsaturated fatty acids (PUFA-PLs). The conversion of PUFA to PUFA-CoA is critical for the synthesis of PUFA-PLs and is reliant on ATP, yet the role of mitochondrial ATP production in regulating ferroptosis remains unclear. In this study, we employed a metabolite deprivation and replenishment system coupled with flow cytometry to investigate the interplay between glutamine metabolism, mitochondrial ATP, and ferroptosis. We demonstrated that depriving cells of glutamine increases intracellular levels of reactive oxygen species (ROS), while also unexpectedly inhibiting ferroptosis induced by cystine deprivation. Mechanistically, glutamine deficiency impaired mitochondrial ATP production, and pharmacological inhibition of mitochondrial ATP export to the cytosol effectively blocked ferroptosis. Further analysis revealed that mitochondrial ATP depletion under glutamine-deficient conditions hindered the conversion of PUFAs to PUFA-CoA, thereby limiting PUFA-PL synthesis and ferroptosis execution. Notably, although glutamine deprivation alone did not directly trigger ferroptosis, it promoted PUFA oxidation and prostaglandin-endoperoxide synthase 2 (PTGS2) expression via ROS accumulation. Together, our findings highlight the critical role of mitochondrial ATP in ferroptosis regulation and provide new insights into the metabolic control of cell death pathways.

Keywords

adenosine triphosphate / ferroptosis / glutamine / mitochondria / reactive oxygen species

References

[1] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht, et al., “Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death,” Cell 149, no. 5 (2012): 1060-1072.

[2] B. R. Stockwell, “Ferroptosis Turns 10: Emerging Mechanisms, Physiological Functions, and Therapeutic Applications,” Cell 185, no. 14 (2022): 2401-2421.

[3] B. R. Stockwell, J. P. Friedmann Angeli, H. Bayir, et al., “Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease,” Cell 171, no. 2 (2017): 273-285.

[4] D. Tang, X. Chen, R. Kang, and G. Kroemer, “Ferroptosis: Molecular Mechanisms and Health Implications,” Cell Research 31, no. 2 (2021): 107-125.

[5] H. Yan, T. Zou, Q. Tuo, et al., “Ferroptosis: Mechanisms and Links With Diseases,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 49.

[6] R. Xu, L. Wang, and S. Qu, “A Novel Mechanism of Ferroptosis Surveillance Offers Promising Therapeutic Avenues for Breast and Prostate Cancers,” Molecular Biomedicine 4, no. 1 (2023): 30.

[7] S. Feng, D. Tang, Y. Wang, et al., “The Mechanism of Ferroptosis and Its Related Diseases,” Molecular Biomedicine 4, no. 1 (2023): 33.

[8] W. S. Yang and B. R. Stockwell, “Ferroptosis: Death by Lipid Peroxidation,” Trends in Cell Biology 26, no. 3 (2016): 165-176.

[9] J. Zheng and M. Conrad, “The Metabolic Underpinnings of Ferroptosis,” Cell Metabolism 32, no. 6 (2020): 920-937.

[10] F. Ursini and M. Maiorino, “Lipid Peroxidation and Ferroptosis: The Role of GSH and GPx4,” Free Radical Biology and Medicine 152 (2020): 175-185.

[11] B. Qiu, F. Zandkarimi, C. T. Bezjian, et al., “Phospholipids With Two Polyunsaturated Fatty Acyl Tails Promote Ferroptosis,” Cell 187, no. 5 (2024): 1177-1190.e18.

[12] J.-Y. Lee, M. Nam, H. Y. Son, et al., “Polyunsaturated Fatty Acid Biosynthesis Pathway Determines Ferroptosis Sensitivity in Gastric Cancer,” Proceedings of the National Academy of Sciences 117, no. 51 (2020): 32433-32442.

[13] S. Doll, B. Proneth, Y. Y. Tyurina, et al., “ACSL4 Dictates Ferroptosis Sensitivity by Shaping Cellular Lipid Composition,” Nature Chemical Biology 13, no. 1 (2017): 91-98.

[14] Y. Li, D. Feng, Z. Wang, et al., “Ischemia-Induced ACSL4 Activation Contributes to Ferroptosis-Mediated Tissue Injury in Intestinal Ischemia/Reperfusion,” Cell Death & Differentiation 26, no. 11 (2019): 2284-2299.

[15] S. S. Sabharwal and P. T. Schumacker, “Mitochondrial ROS in Cancer: Initiators, Amplifiers or an Achilles' Heel?,” Nature Reviews Cancer 14, no. 11 (2014): 709-721.

[16] B. Hassannia, P. Vandenabeele, and T. Vanden Berghe, “Targeting Ferroptosis to Iron Out Cancer,” Cancer Cell 35, no. 6 (2019): 830-849.

[17] J. Watson, “Oxidants, Antioxidants and the Current Incurability of Metastatic Cancers,” Open Biology 3, no. 1 (2013): 120144.

[18] A. Bansal and M. C. Simon, “Glutathione Metabolism in Cancer Progression and Treatment Resistance,” Journal of Cell Biology 217, no. 7 (2018): 2291-2298.

[19] Y. P. Kang, A. Mockabee-Macias, C. Jiang, et al., “Non-Canonical Glutamate-Cysteine Ligase Activity Protects Against Ferroptosis,” Cell Metabolism 33, no. 1 (2021): 174-189.e7.

[20] C. S. Shin, P. Mishra, J. D. Watrous, et al., “The Glutamate/Cystine xCT Antiporter Antagonizes Glutamine Metabolism and Reduces Nutrient Flexibility,” Nature Communications 8 (2017): 15074.

[21] L. A. Timmerman, T. Holton, M. Yuneva, et al., “Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target,” Cancer Cell 24, no. 4 (2013): 450-465.

[22] T. Gong, C. Zheng, X. Ou, et al., “Glutamine Metabolism in Cancers: Targeting the Oxidative Homeostasis,” Frontiers in Oncology 12 (2022): 994672.

[23] I. Ingold, C. Berndt, S. Schmitt, et al., “Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis,” Cell 172, no. 3 (2018): 409-422.e21.

[24] W. S. Yang, R. SriRamaratnam, M. E. Welsch, et al., “Regulation of Ferroptotic Cancer Cell Death by GPX4,” Cell 156, no. 1-2 (2014): 317-331.

[25] M. Gao, J. Yi, J. Zhu, et al., “Role of Mitochondria in Ferroptosis,” Molecular Cell 73, no. 2 (2019): 354-363.e3.

[26] A. Ibrahim, N. Yucel, B. Kim, and Z. Arany, “Local Mitochondrial ATP Production Regulates Endothelial Fatty Acid Uptake and Transport,” Cell Metabolism 32, no. 2 (2020): 309-319.e7.

[27] B. Gan, “ACSL4, PUFA, and Ferroptosis: New Arsenal in Anti-Tumor Immunity,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 128.

[28] X. Chen, C. Zhao, X. Li, et al., “Terazosin Activates Pgk1 and Hsp90 to Promote Stress Resistance,” Nature Chemical Biology 11, no. 1 (2015): 19-25.

[29] T. J. J. Schirris, T. Ritschel, G. Herma Renkema, P. H. G. M. Willems, J. A. M. Smeitink, and F. G. M. Russel, “Mitochondrial ADP/ATP Exchange Inhibition: A Novel Off-Target Mechanism Underlying Ibipinabant-Induced Myotoxicity,” Scientific Reports 5 (2015): 14533.

[30] J. J. Ruprecht and E. R. S. Kunji, “The SLC25 Mitochondrial Carrier Family: Structure and Mechanism,” Trends in Biochemical Sciences 45, no. 3 (2020): 244-258.

[31] X. Jiang, B. R. Stockwell, and M. Conrad, “Ferroptosis: Mechanisms, Biology and Role in Disease,” Nature Reviews Molecular Cell Biology 22, no. 4 (2021): 266-282.

[32] M. M. Gaschler and B. R. Stockwell, “Lipid Peroxidation in Cell Death,” Biochemical and Biophysical Research Communications 482, no. 3 (2017): 419-425.

[33] H. R. Freitas, A. R. Isaac, R. Malcher-Lopes, B. L. Diaz, I. H. Trevenzoli, and R. A. De Melo Reis, “Polyunsaturated Fatty Acids and Endocannabinoids in Health and Disease,” Nutritional Neuroscience 21, no. 10 (2018): 695-714.

[34] M. Conrad and D. A. Pratt, “The Chemical Basis of Ferroptosis,” Nature Chemical Biology 15, no. 12 (2019): 1137-1147.

[35] M. Carbone and G. Melino, “Lipid Metabolism Offers Anticancer Treatment by Regulating Ferroptosis,” Cell Death & Differentiation 26, no. 12 (2019): 2516-2519.

[36] P. Liao, W. Wang, W. Wang, et al., “CD8(+) T Cells and Fatty Acids Orchestrate Tumor Ferroptosis and Immunity via ACSL4,” Cancer Cell 40, no. 4 (2022): 365-378.e6.

[37] Y. Wang, M. Zhang, R. Bi, et al., “ACSL4 Deficiency Confers Protection Against Ferroptosis-Mediated Acute Kidney Injury,” Redox Biology 51 (2022): 102262.

[38] Q. Tuo, Y. Liu, Z. Xiang, et al., “Thrombin Induces ACSL4-dependent Ferroptosis During Cerebral Ischemia/Reperfusion,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 59.

[39] H. L. Zhang, B. X. Hu, Z. L. Li, et al., “PKCβII Phosphorylates ACSL4 to Amplify Lipid Peroxidation to Induce Ferroptosis,” Nature Cell Biology 24, no. 1 (2022): 88-98.

[40] B. J. Altman, Z. E. Stine, and C. V. Dang, “From Krebs to Clinic: Glutamine Metabolism to Cancer Therapy,” Nature Reviews Cancer 16, no. 10 (2016): 619-634.

[41] M. Gao, P. Monian, N. Quadri, R. Ramasamy, and X. Jiang, “Glutaminolysis and Transferrin Regulate Ferroptosis,” Molecular Cell 59, no. 2 (2015): 298-308.

[42] H. Lee, F. Zandkarimi, Y. Zhang, et al., “Energy-Stress-Mediated AMPK Activation Inhibits Ferroptosis,” Nature Cell Biology 22, no. 2 (2020): 225-234.

[43] C. S. Zhang, S. A. Hawley, Y. Zong, et al., “Fructose-1,6-Bisphosphate and Aldolase Mediate Glucose Sensing by AMPK,” Nature 548, no. 7665 (2017): 112-116.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).